Matrix metalloproteinase-2 and -9 in the sera and in the urine of human oncocytoma and renal cell carcinoma

Oncology Reports

Volumn 28, Issue 3, 2012, Pages 1051-1056

  Di Carlo, Angelina ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Clear cell renal cell carcinoma; Matrix metalloproteinase 2; Matrix metalloproteinase 9; Oncocytoma; Serum; Urine

Indexed keywords

GELATINASE A; GELATINASE B;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; ONCOCYTOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN URINE LEVEL; URINALYSIS; ZYMOGRAPHY;

ADENOMA, OXYPHILIC; ADULT; AGED; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; ENZYME ASSAYS; FEMALE; GELATIN; HUMANS; KIDNEY NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 84865322999     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1864     Document Type: Article

References (23)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Cohen HT and McGoven FJ: Renal-cell carcinoma. N Engl J Med 353: 2477-2490, 2005.
3. Nagase H and Woessner JF: Matrix metalloproteinases. J Biol Chem 274: 21491-21494, 1999.
4. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
5. Björklund M and Koivunen E: Gelatinase-mediated migration and invasion of cancer cell. Biochim Biophys Acta 1755: 37-69, 2005.
6. Sobin LH and Wittekind CH (eds): International Union Against Cancer (UICC) TNM classification of malignant tumors. 6th edition. Wiley-Liss, New York, NY, pp193-195, 2002.
7. Bradford MM: A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem 72: 248-254, 1976.
8. Di Carlo A, Terracciano D, Mariano A and Macchia V: Urinary gelatinase activities (matrix metalloproteinase 2 and 9) in human bladder tumors. Oncol Rep 15: 1321-1326, 2006.
9. Di Carlo A, Terracciano D, Mariano A and Macchia V: Matrix metalloproteinase-2 and matrix metalloproteinase-9 type IV collagenases in serum of patients with pleural effusions. Int J Oncol 26: 1363-1368, 2005.
10. 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett 314: 386-388, 1992.
11. Yan L, Borregaard N, Kjeldsen L and Moses MA: The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP and neutrophil gelatinase-associated lipocalin (NGAL). J Biol Chem 276: 37258-37265, 2001.
12. Roy R, Louis GL, Loughlin KR, Wiederschain D, Kilroy SM, Lamb CC, Zurakowski D and Moses MA: Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res 14: 6610-6617, 2008.
13. Goldberg GI, Strongin A, Collier IE, Genrich LT and Marmer BL: Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of proenzyme with stromelysin. J Biol Chem 267: 4583-4591, 1992.
14. Russo P: Localized renal cell carcinoma. Curr Treat Options Oncol 2: 447-455, 2001.
15. Kashyap MK, Kumar A, Emelianenko N, Kaahyap A, Kaushik R, Huang R, Khullar M, Sharma SK, Singh SK, Bhargave AK and Upadhyava SK: Biochemical and molecular markers in renal cell carcinoma: an update and future prospects. Biomarkers 10: 258-294, 2005.
16. Struckmann K, Mertz K, Steu S, Storz M, Staller P, Krek W, Schraml P and Moch H: pVHL co-ordinately regulates CXCR4/ CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma. J Pathol 214: 464-471, 2008.
17. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N and Ross JS: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7: 3113-3119, 2001.
18. Abdel-Wahed MM, Asaad NY and Aleskandarany M: Expression of matrix metalloproteinase-2 in renal cell carcinoma. J Egypt Nat Canc Inst 16: 168-177, 2004.
19. Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun HJ and Ringert RH: Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol 160: 1914-1918, 1998.
20. Kamiya N, Kishimoto T, Suzuki H, Sekita N, Nagai Y, Oosumi N, Kito H, Tochigi N, Shinbo M, Nemori R, et al: increased in situ gelatinolytic activity in renal cell tumor tissues correlates with tumor size, grade and vessel invasion. Int J Cancer 106: 480-485, 2003.
21. Lein M, Jung K, Laube C, Hübner T, Winkelmann B, Stephan C, Hauptmann S, Rudolph B, Schnorr D and Loening SA: Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. Int J Cancer 85: 801-804, 2000.
22. Cannon GM and Getzenberg RH: urinary matrix metalloproteinases activity is not significantly altered in patients with renal cell carcinoma. Urology 67: 848-850, 2006.
23. Sherief MH, Low SS, Miura M, Kudo N, Novick A and Weimbs T: Matrix metalloproteinase activity in urine of patients with renal cell carcinoma leads to degradation of extracellular matrix proteins: possible use as a screening assay. J Urol 169: 1530-1534, 2003.